☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. (1) Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark whether the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the ~~Act:~~Securities and Exchange Act of 1934:

As of ~~May 15,~~August 13, 2019, there were ~~131,425,194~~322,230,038 shares of common stock, par value $0.001, of the registrant issued and outstanding.

The Unaudited Consolidated Financial Statements of Natur International Corp., a Wyoming corporation (the “Company,” “Natur,” “we,” “our,” “us” and words of similar import) were prepared by management and commence on the following page, together with related notes. In the opinion of management, the Unaudited Consolidated Financial Statements fairly present the financial condition of the Company.

	NOTES	March 31, 2019 (unaudited)			December 31, 2018			NOTES	(unaudited) June 30, 2019			December 31, 2018
ASSETS
Current Assets
Cash and cash equivalents			18,600			128,364				1,028,877			128,364
Accounts receivable			8,619			42,744				2,628			42,744
Related party receivable	4		1,796			1,833				-			1,833
Inventories			103,396			179,072				24,483			179,072
Other current assets	5		78,492			99,535		5		60,274			99,535

Current assets held for disposal	13		339			377,628		13		5,000			377,628
Total Current Assets			211,242			829,176				1,121,262			829,176

Non-Current Assets
Intangible asset			21,793			37,353				37,353			37,353
Fixed assets			256,592			523,510
Other assets			176,350			201,160
Right-of-use asset			580,310			-
Fixed asset								4		58,685			523,510
Other asset										-			201,160
Non-current assets held for disposal			-			51,165		13		-			51,165
Total Non-Current Assets			1,035,045			813,188				96,038			813,188

TOTAL ASSETS			1,246,287			1,642,364				1,217,300			1,642,364

LIABILITIES AND MEMBERS’ DEFICIT

Current Liabilities
Accounts Payable			1,341,652			1,127,345				426,891			1,127,345
Accrued expenses & other contingent liabilities	6		623,318			583,161		6		106,387			583,161
Related party other liabilities	7		2,217,440			2,032,705		7		2,809,939			2,032,705
Related party other notes	8		1,062,426			1,072,849		8		2,984,017			1,072,849
Convertible note payable	9		2,159,680			1,600,710		9		1,202,849			1,600,710
Related party convertible note payable	10		11,436,228			11,671,743		10		-			11,671,743
Operating lease liabilities			263,013			-
Preferred Stock payable										2,064,736			-
Current liabilities held for disposal	13		151,267			887,126		13		170,469			887,126
Total Current Liabilities			19,255,024			18,975,639				9,765,288			18,975,639

Non-Current Liabilities
Operating lease liabilities			314,994			-
Total Non-Current Liabilities			314,994			-

TOTAL LIABILITIES			19,570,018			18,975,639				9,765,288			18,975,639

Retained Deficit
Common stock, $0.001 par value, 200,000,000 shares authorized, 131,424,194 and 129,049,192 issued and outstanding as of March 31, 2019 and December 31, 2018 respectively.			131,425			129,049
Preferred stock A, $0.001 par value, 2,469.131 shares authorized, 2,397.131 and 2,469.131 issued and outstanding as of March 31, 2019 and December 31, 2018 respectively. Convertible to common stock at a 1:33,000 ratio.			2			2
Preferred stock B, $0.001 par value, 100,000 shares authorized, 100,000 and 100,000 issued and outstanding as of March 31, 2019 and December 31, 2018 respectively. Convertible to common stock at a 1:1000 ratio.			100			100
Stockholders’ Equity
Common stock, $0.001 par value, 750,000,000 and 200,000,000 shares authorized as of June 30, 2019 and December 31, 2018, respectively. 310,597,593 and 129,049,192 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively.										310,597			129,049
Preferred stock A, $0.001 par value, 2,397.131 and 2,469.131 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively. Convertible to common stock at a 1:33,000 ratio.										2			2
Preferred stock B, 100,000 shares authorized, Nil and 100,000 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively. Convertible to common stock at a 1:1000 ratio.										-			100
Preferred stock C, $0.001 par value, Nil issued and outstanding as of June 30, 2019 and December 31, 2018, respectively. Convertible to common stock at a 1:1000 ratio.										-			-
Additional Paid in Capital			5,575,055			5,174,269				14,924,725			5,174,269
Total Shareholders’ deficit			(24,047,101	)		(22,299,570	)			(23,850,777	)		(22,299,570	)
Accumulated other comprehensive loss			16,788			(337,125	)			67,465			(337,125	)
TOTAL DEFICIT			(18,323,731	)		(17,333,275	)
TOTAL EQUITY/(DEFICIT)										(8,547,988	)		(17,333,274	)

LIABILITIES AND MEMBERS’ DEFICIT			1,246,287			1,642,364				1,217,300			1,642,364

The accompanying notes are an integral part of these consolidated financial statements

Natur International ~~Corp~~Corp. was formerly named Future Healthcare of America. In November 2018, Natur Holding B.V. was acquired to continue the company as a provider of cold pressed juice beverages and healthy snacks. The original business of Future Healthcare of America, ~~was~~ founded in 2012, ~~and~~ was ~~traded with stock ticker symbol FUTU. Future Healthcare of America was~~as a provider of home healthcare services, ~~including senior care, occupational~~which had declined and ~~speech therapy,~~is expected to be fully closed and ~~pediatric nursing services.~~liquidated in the third quarter of 2019.

The current name ~~change took place following~~of the ~~consummation~~company is Natur International Corp., which was effected on January 7, 2019. The trading symbol for our common stock became NTRU as of ~~acquisition~~that date and trades on The OTC Market.

Natur International Corp., is a Wyoming corporation, and operates its beverage business through a number of direct and indirect subsidiaries, of which the current principal one is Natur BPS B.V. (known by the trade name Natur Functionals), and is the successor to the business of Natur Holding B.V. ~~and became effective Monday, January 7. The stock ticker symbol has become NTRU. Currently the healthcare services are being wound down.~~

~~Natur Holding B,V.~~ (“we”, “our”, “the Company” or “Natur”) ~~was founded~~. Our beverage business commenced in late 2015, ~~and has its~~with product distribution in Northern Europe. Currently, our operational headquarters is in Amsterdam, the Netherlands.

At the onset of ~~the quarter,~~2019, our product line up centered on a range of cold pressed juices and healthy snacks. These products were sold either directly or through distribution partners in the Netherlands and the United Kingdom. Beginning in the fourth quarter of 2018, and throughout the first ~~quarter~~half of 2019, the Company focus shifted from dependence on the legacy fruit and vegetable juices and snacks toward innovating a new line of hemp-derived natural food and beverage products. The Company ~~products~~product value proposition is to ~~affordably~~ provide ~~the most~~affordable, culturally relevant, authentic, fresh fruit, vegetable and hemp-derived ~~supplement~~supplemented consumer products to democratize clean, healthy, eating and drinking, ~~occasions,~~ with plans to address the growing needs for products that address other personal needs in health, wellness and beauty care.

Through third party contract manufacturers, we apply patented technology to proprietary nutrient dense blends of fruit and vegetables, adding hemp-derived supplements. These are bottled or packed with technically advanced food and product safety measures and in some cases cold high-pressure processing to bring fresh tasting fruit, vegetable and hemp-derived ~~supplement~~supplemented blends to market through more than fifteen product types. These newly innovated products are brought to market, in Europe, through Natur’s distribution channels of direct-to-business, direct-to-consumer and through select distributors.

Natur operated as a private enterprise in the Netherlands from its founding in 2015 through November 13, 2018, when it was acquired as a wholly owned subsidiary in a share exchange transaction by Future Healthcare of America, ~~on November 13, 2018, contemplated by~~pursuant to that certain Share Exchange Agreement, among the Company and the former shareholders of Natur Holding, B.V. (the “Share Exchange Transaction”). In connection with the Share Exchange Transaction, the former shareholders of Natur received the equivalent of 215,759,999 shares of the Common Stock (the “Common Stock”), which was issued in part as 115,760,000 shares of Common Stock and in part as 100,000 shares of voting, convertible Series B Preferred Stock (the “Series B Preferred Stock”) representing 100,000,000 shares of Common Stock upon conversion. The Series B Preferred Stock will convert automatically upon the Company increasing the number of shares of Common Stock of its authorized capital, which it plans to do promptly so as to cause the conversion of the Series B Preferred Stock. Immediately after the Share Exchange Transaction ~~the former Natur shareholders collectively own the controlling position among the shareholders of the Company~~

~~The merger~~ was accounted for as a reverse capitalization with Natur Holding BVB.V. being treated as the accounting acquirer. As such, the historical information for all periods presented prior to the merger date relate to Natur Holding ~~BV.~~B.V. Subsequent to the ~~merger~~Share Exchange Transaction consummation date, the information in this report relates to the consolidated entities of Natur, ~~with its subsidiary~~including Natur Holding BVB.V. and successor subsidiary and the former subsidiaries of Future Healthcare of America, ~~that~~the latter of which are currently in the process of being wound down and presented as discontinued operations.

In connection with the ~~acquisition,~~Share Exchange Transaction, net cash received was $2,000,000 and costs incurred were $399,381 including professional fees for legal, accounting services and finance commission. Immediately after the Share Exchange Transaction, the former Natur shareholders collectively owned the controlling position among the shareholders of the Company.

On May 1, 2019, Natur Holding B.V. filed a Petition in the Netherlands Court for the District of Amsterdam (“Petition”) for the liquidation of the company and the transfer of certain assets and retained liabilities to Natur BPS B.V., a wholly owned subsidiary of Natur International Corp., which operates under the trade name Natur Functionals. This court process allowed the historical business of the Company’s beverage business to be continued and eliminates a substantial amount of the liabilities of the Company. The Petition permits the Company to focus on activities that will drive growth and future profits. As a result of the Petition the control of Natur International Corp. over Natur Holding B.V. is compromised for financial reporting purposes, and its investment in it will be deconsolidated as of May 1, 2019.

The Series B Preferred Stock was automatically converted upon the Company increasing the number of shares of Common Stock of its authorized capital, which happened on June 26, 2019. At the same time the Series C Preferred Stock was automatically converted to 78,832,399 shares of Common Stock. As of June 30, 2019, the total number of outstanding shares amounted to 310,597,593 shares of Common Stock with an authorized share capital of 750,000,000 shares of common Stock.

During the first half of the 2019 fiscal year, in addition to pursuing the Petition to reorganize certain of its liabilities, the Company successfully has negotiated to convert a further $6,114,790 of debt into 149,516,865 shares of common stock to be issued in due course. More importantly, it has been conducting substantial fund-raising activities. It has obtained new funding through a series of securities purchase agreements that have been funded in the amount of $2,064,736 or are subject to signed commitments for funding in the amount of $3,283,904 that is expected to be completed during the third fiscal quarter of 2019. The securities to be sold will be a mix of several new series of preferred stock convertible into up to 96,289,473 shares of Common Stock and warrants exercisable for up to 177,404,377 shares of Common Stock.

On June 30, 2019, the Company expressed its interest in pursuing a transaction with Share International Holding B.V. on a binding basis. The contemplated transaction would be an acquisition of Share International Holding B.V. (“SIH”) and related assets for the operation of its business by the issuance of shares of Natur. The terms of this potential acquisition have yet to be negotiated and finalized, and the overall transaction is subject to conditions precedent at this time. At the same time as the Company entered into the letter of intent, it lent to SIH the sum $250,000 under a promissory note, due January 4, 2020. The note bears interest at the rate of 10%. The repayment obligation under the Note will be cancelled if no business arrangement is concluded due to a breach by the Company of any agreement for the business arrangement that is concluded in the future, either party to the note experiences a material adverse change, or the business arrangement is not approved by the shareholders or owners of the respective parties to the extent that approval is required. The note also has other standard default provisions under which the Company may declare a default. Also, at the same time as the foregoing letter of intent and loan were concluded, the board of directors of the Company appointed Mr. Paul Bartley as the Chief Executive Officer of the Company; Mr. Bartley is a principal of SIH.

Basis of presentation.The Company prepares its financial statements using the accrual basis of accounting in accordance with United States generally accepted accounting principles (“US GAAP”).

Consolidation-The financial statements presented reflect the accounts of Natur ~~Holding B.V.~~International Corp and ~~it’s~~its direct orand indirect subsidiaries. All inter-company transactions have been eliminated in consolidation.

Use of Estimates in Financial Statement Preparation.The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents. Cash equivalents include all highly liquid investments with original maturities of three months or less.

Accounts Receivable. Accounts receivable are comprised of unsecured amounts due from customers. The Company carries its accounts receivable at their face amounts less an allowance for bad debts. The allowance for bad debts is recognized based on management’s estimate of likely losses per year, based on past experience and review of customer profiles and the aging of receivable balances.

Inventory.Inventory, consisting of raw materials, work in progress and finished goods, is valued at the lower of the inventory’s costs or net realizable value, using the first in, first out method to determine the cost. Management compares the cost of inventory with its net realizable value and an allowance is made to write down inventory to net realizable value, if lower.

Property and Equipment. Property and equipment are valued at cost. Additions are capitalized and maintenance and repairs are charged to expense as incurred. Gains and losses on dispositions of equipment are reflected in operations. Depreciation is provided using the straight-line method over the estimated useful lives of the assets as follows:

Intangible Assets and Long-Lived Assets.The Company recognizes an acquired intangible asset apart from goodwill whenever the intangible asset arises from contractual or other legal rights, or when it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their useful lives. Impairment losses are recognized if the carrying amount of an intangible asset subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.

The Company’s long-lived assets, including intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Long lived assets are evaluated on a yearly basis and no impairment losses were incurred during the ~~three~~six months ended ~~March 31,~~June 30, 2019.

Related Party Transactions.The Board of Directors has adopted a Related Party Transaction Policy for the review of related person transactions. Under these policies and procedures, the management reviews related person transactions in which we are or will be a participant to determine if they are fair and beneficial to the Company. Financial transactions, arrangements, relationships or any series of similar transactions, arrangements or relationships in which a related person has or will have a material interest and that exceeds the lesser of: (i) $10,000, and (ii) one percent of the average of the Company’s total assets at year-end for the last two completed fiscal years, in the aggregate per year are subject to the boards review. Any member of the board who is a related person with respect to a transaction under review may not participate in the deliberation or vote requesting approval or ratification of the transaction. Transactions that are subject to the policy include any transaction, arrangement or relationship (including indebtedness or guarantees of indebtedness) in which the Company is a participant with a related person. The related person may have a direct or indirect material interest in the transaction. It is Company policy that the board shall approve any related party transaction before the commencement of the transaction. However, if the transaction is not identified before commencement, it must still be presented to the board for their review and ratification.

Revenue Recognition. Beginning on January 1, 2018, the Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle:

Step 4: Allocate the transaction price to the performance obligations in the contract

The Company’s performance obligations are satisfied at the point in time when products are received by the customer, which is when the customer has title and the significant risks and rewards of ownership. Therefore, the Company’s contracts have a single performance obligation (shipment of product). The Company primarily receives fixed consideration for sales of product.

The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon delivery to the customer. The Company’s performance obligations are satisfied at that time.

Share-Based Payment ~~Arrangement.~~Arrangements. The Company measures the cost of employee services received in exchange for an award of equity instruments (share-based payments, or SBP) based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the SBP award—the requisite service period (vesting period). For SBP awards subject to conditions, compensation is not recognized until the performance condition is probable of occurrence. The grant-date fair value of share options is estimated using the Black-Scholes-Merton option-pricing model. The Company adopted ASU 2018-07 in the first quarter of 2019 which aligns the accounting for share-based payment awards issued to employees and non-employees.

The fair value of each option granted during the period ended ~~March 31,~~June 30, 2019 was estimated on the date of grant using the Black-Scholes-Merton option-pricing model with the weighted average assumptions in the following table:

The expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected volatility was based on the volatility in the trading of the Company’s common stock. The assumed discount rate was the default risk-free six-year interest rate in the Netherlands.

The Company’s products are sold and distributed through various channels, which include selling directly to retail stores and other outlets such as food markets, institutional accounts and independent outlets. The Company typically collects payment from customers within 30 days from the date of sale. The following table presents our continued revenues disaggregated by geographical region for the six-month period ended ~~March 31,~~June 30, 2019:

The Company sells its products and extends credit, generally without requiring collateral, based on an ongoing evaluation of the customer’s business prospects and financial condition. The Company evaluates the collectability of its trade accounts receivable based on a number of factors, including the Company’s historic collections pattern and changes to a specific customer’s ability to meet its financial obligations. The Company has established an allowance for doubtful accounts to adjust the recorded receivable to the estimated amount the Company believes will ultimately be collected.

The nature of the Company’s contracts does not give rise to variable consideration, such as prospective and retrospective rebates.

The Company experiences customer returns primarily as a result of damaged or out-of-date product. At any given time, the Company estimates less than 1% of sales could be at risk for return by customers. As the company do not deem this amount to be material no provision was recorded for the period ended ~~31 March,~~30 June, 2019. Returned product is recognized as a reduction of net sales.

Compensation—Stock Compensation:On June 20, 2018, the FASB issued ASU No. 2018-07,Compensation—Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting,which aligns the accounting for share-based payment awards issued to employees and nonemployees. Under ASU No. 2018-07, the existing employee guidance will apply to nonemployee share-based transactions (as long as the transaction is not effectively a form of financing), with the exception of specific guidance related to the attribution of compensation cost. The cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services. In addition, the contractual term will be able to be used in lieu of an expected term in the option-pricing model for nonemployee awards. The adoption had no impact on the Company’s historic financial statements.

Leases:In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. This update requires the recognition of lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous guidance. The accounting for finance leases (capital leases) was substantially unchanged. The original guidance required application on a modified retrospective basis with adjustments to the earliest comparative period presented. In August 2018, the FASB issued ASU No. 2018-11, “Targeted Improvements to ASC 842,” which included an option to not restate comparative periods in transition and elect to use the effective date of ASU No. 2016-02 as the date of initial application, which the Company elected. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, and continues to be reported under previous guidance that did not require the recognition of operating lease liabilities and corresponding lease assets on the consolidated balance sheet. As a result of the adoption of ASU No. 2016-02 on January 1, 2019, the Company recorded operating lease right-of-use assets of $580,310 and operating lease liabilities of $578,007. The adoption of ASU No. 2016-02 had an immaterial impact on the Company’s condensed consolidated statement of income and c consolidated statement of cash flows for the three-month period ended March 31, 2019. In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company to carry forward the historical lease classification, not reassess prior conclusions related to expired or existing contracts that are or that contain leases, and not reassess the accounting for initial direct costs.

Foreign Currency Translation.The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

The financial records of the Company are maintained in its local currency, the euro (“EUR”), which is the functional currency. Assets and liabilities are translated from the local currency into the reporting currency, U.S. dollars, at the exchange rate prevailing at the balance sheet date. Revenues and expenses are translated at weighted average exchange rates for the period to approximate translation at the exchange rates prevailing at the dates those elements are recognized in the consolidated financial statements. Foreign currency translation gain (loss) resulting from the process of translating the local currency financial statements into U.S. dollars are included in determining accumulated other comprehensive income in the consolidated statement of stockholders’ equity.

Unless otherwise noted, the rate presented below per U.S. $1.00 was the midpoint of the interbank rate as quoted by OANDA Corporation (www.oanda.com) contained in its consolidated financial statements. Translation of amounts from EUR into U.S. dollars has been made at the following exchange rates for the respective periods:

Cost of Revenues. Cost of revenue includes all direct expenses incurred to produce the revenue for the period. This includes, but is not limited to, costs for finished products, pick packing costs, storage costs and transportation costs. Cost of revenues are recorded in the same period as the resulting revenue.

Employee Benefits. Wages, salaries, bonuses and social security contributions are recognized as an expense in the year in which the associated services are rendered by employees. For any unused portion of vacation leave, an accrual is recorded for carry over to the following year.

Income Taxes. The Company is subject to US corporation tax. The US combined federal and state corporate tax rate is 23%. The company’s United States net operating losses totaled $3,483,928 as of December 31, 2017 and begin to expire in tax years 2032 and following. Net losses from US operating totaled $157,386 for 2018 and may be carried forward indefinitely. The company is subject to US Internal Revenue Code rules limiting the use of US net operating losses after the merger with Future Health Care of America during 2018 (described in Note 17). This limitation has no effect on the Company’s financial statements because the Company has recognized no deferred tax asset with respect to its net operating loss carryforwards. The NOLs are the cumulative NOL’s per the Company’s 2017 federal income tax return. The 382 limit will not be factored in until the company has income and the limit is therefore applicable.

Natur ~~Holding,~~BPS B.V., the Dutch subsidiary of Natur International Corp is structured as a Dutch limited liability company. Tax on the result is calculated based on the result before tax in the profit and loss account, ~~taking into account~~considering losses available for set-off from previous years (to the extent that they have not already been included in the deferred tax assets) and exempt profit components and after the addition of non-deductible costs. Due account is also taken of changes which occur in the deferred tax assets and deferred tax liabilities in respect of changes in the applicable tax rate.

The corporate tax rate for profits above $238,812 (or €200,000) amounts to 25%. Below that amount the rate is 20%. Future profits can be carried back to prior year losses for a maximum of 9 years for the full amount of losses incurred.

In the financial statements of group companies, a tax charge is calculated on the basis of the accounting result. The corporate income tax that is due by these group companies is charged into the current accounts of the company.

Because of the compensable losses no deferred taxes are included in the financial statements. From incorporation of the company only the Corporation Tax return of 2015/2016 has been filed. All years are still subject to examination.

Fair Value of Financial Instruments.The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, and short-term notes approximate fair value due to the relatively short period to maturity for these instruments. The long-term debt approximate fair value since the related rates of interest approximate current market rates.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs.

The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

Income /(Loss) Per Share- The Company computes income (loss) per share in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260 Earnings Per Share, which requires the Company to present basic earnings per share and diluted earnings per share when the effect is dilutive (see Note ~~13)~~12).

The Company considered its going concern disclosure requirements in accordance with ASC 240-40-50. ~~The Company concluded that its negative~~We have had material operating losses, working capital deficit and ~~decreased~~have not yet created positive cash ~~flows from operations are conditions that raised~~flows. These factors raise substantial doubt ~~about the Company’s~~as to our ability to continue as a going concern. ~~Without a~~The Company concluded, in spite of the decreased cash flow from operations, both the elimination of certain debt and the successful ~~plan in place from management these conditions could negatively impact~~raising of new capital and obtaining new capital commitments during the ~~Company’s ability~~second quarter of 2019, that it has materially improved its capital so as to ~~meets its financial obligations over the next year. In response, the~~continue as going concern. The Company ~~has~~ implemented a plan in the second quarter of 2019 to ~~alleviate such reasonable doubt~~further structurally improve the conditions for its continuing as ~~follows:~~a going concern; (i) the Company implemented certain cost savings, primarily to its overhead requirements, (ii) the Company will continue to generate additional revenue (and positive cash flows from operations) partly related to the Company’s expansion into new product lines during 2019 and partly related to the Company ~~wide~~ sales initiatives already implemented; ~~(ii) in addition cost saving initiatives~~ and ~~an organization~~(iii) undertook a reorganization and restructuring program to reduce its debt that has now been completed. The corporate restructuring through the Petition in May 2019 is ~~almost completed, will~~further disclosed in Note 13 to these financial statements. These actions have had an ~~additional~~overall positive impact on the cost-basis of the organization. Notwithstanding the foregoing, the Company will ~~seek~~continue to need additional capital ~~as needed, which may be either equity or debt, or both. The Company does not have any capital sources determined at this time,~~from investors to fund its larger business plan and ~~capital may not be available when sought.~~maintain the continuity and growth of its current operations. The accompanying financial statements have been prepared assuming that the ~~company~~Company will continue as a going concern. ~~The company is currently undertaking a corporate restructuring exercise, which is further disclosed in Note 15 – subsequent events.~~

~~Receivables of related parties~~Property, equipment and intangible assets at ~~March 31,~~June 30, 2019, and December 31, 2018, consisted of the following:

Other current assets at ~~March 31,~~June 30, 2019 and December 31, 2018 consisted of the following:

Accrued expenses & other contingent liabilities at ~~March 31,~~June 30, 2019 and December 31, 2018 consisted of the following:

Related party other liabilities at ~~March 31,~~June 30, 2019 and December 31, 2018 consisted of the following:

For the outstanding amount relating to AMC this transaction relates to the purchase of bottled juices for resale. Total purchases relating to goods sold for the ~~three-month~~six-month period ended ~~March 31,~~June 30, 2019 and the ~~three-month~~six-month period ended ~~March 31,~~June 30, 2018 was ~~$31,726,~~$41,130, and ~~$581,997,~~$797,770, respectively.

For the ~~loan~~related party balance liability held from NL Life Sciences, ~~and~~ STB Family Offices SARL and TriDutch Holding B.V there is no repayment schedule in place. ~~The~~No interest ~~rate~~ is ~~charged on~~being charged. For the ~~basis~~related party liability held with Flare Media B.V., STB Family Office B.V. in May 2019 the debt was fully transferred to NL Life Sciences B.V. as part of ~~EURIBOR + 3% on~~a debt restructuring. This balance will be converted into equity in the ~~average balance~~third quarter of ~~the loan.~~2019.

The other loans consist of the procurement of ~~juices~~goods and consulting fees for the management ~~team.~~team that have accrued from previous periods. No interest is being charged.

Loan from other related parties at ~~March 31,~~June 30, 2019 and December 31, 2018 consisted of the following:

	March 31, 2019		December 31, 2018		June 30, 2019		December 31, 2018

Efficiency Life Fund		392,641		400,750		2,984,017		400,750
TriDutch Holding B.V.		669,785		672,099		-		672,099
		1,062,426		1,072,849		2,984,017		1,072,849

For the loan from ~~Tridutch~~TriDutch Holding B.V., ~~there is no repayment schedule~~ in ~~place. The interest rate is charged on~~May 2019 the ~~basis~~debt was fully transferred to NL Life Sciences B.V. as part of ~~EURIBOR + 3% on the average balance of the loan. In 2018 accrued interest of $17,249 was added to the balance and additional borrowings of $128,043 were drawn down, partly offset by~~ a positive exchange rate difference of $25,283. In 2019 accrued interest of $2,314 was added to the balance and no additional borrowings were drawn down, no repayments were made on the balance in either 2018 or 2019.debt restructuring.

For the loan from Efficiency Life Fund there is a repayment schedule in place to repay the loan in 10 installments from July 2019 to April ~~2020. The entire balance of 400,750 was drawn down in 2018 with no repayments made on~~2022 and the ~~balance~~debt therefore transferred from a related party liability to ~~date. The movement in 2019 relates wholly to exchange rate difference.~~a loan.

Convertible loans payable at ~~March 31,~~June 30, 2019 and December 31, 2018 consisted of the following:

	March 31, 2019		December 31, 2018		June 30, 2019		December 31, 2018

Convertible loan 1		632,695		629,750		636,614		629,750
Convertible loan 2		962,285		970,960		-		970,960
Convertible loan 3		564,700		-		566,235		-
		2,159,680		1,600,710		1,202,849		1,600,710

Party for loan 1 ~~has~~had granted a loan facility in the principle amount of $581,058 or €500,000 with the right, but not the obligation to convert the outstanding loan amounts into shares in the capital of Natur at a company valuation of $17.4 million or €15 million for a term from December 19, 2017, till the maturity date of December 31, 2018, at an interest rate of 10% per annum. ~~No further drawdowns were made on~~In July 2019 the ~~loan in 2018 or 2019 and the increased balance is due~~amount was fully converted to ~~the accrued interest as no repayment for capital or interest have been made. The lender has agreed to a term sheet for conversion~~common stock of the ~~debt into common stock at May 7, 2019. Please refer to Note 15, subsequent events.~~company.

On October 20, 2017, an amount of $929,692 or €800,000 was advanced to the Company for a loan agreement that was drafted but never signed. An interest rate of 5% per annum is calculated and the loan has a maturity date of February 28, 2018. ~~The loan is convertible~~Repeated attempts at correspondence was made between the Company and the lender’s attorney in April and May 2019 to ~~shares~~discuss converting the balance to Common Stock of the Company on the bankruptcy of Natur at a company valuation of $23.3 million or €20 million. The loan is in default and lender has demanded payment and does not want to convert. No further drawdowns were made on the loan in 2018 or 2019 and the decreased balance is due to favorable movement in the exchange rate offsetting the additional accrued interestHolding B.V. as no ~~repayment for capital or interest have been made.~~response was received the amount remains in Natur Holding B.V. who’s estate is being managed independently by a court issued Curator.

Natur Holding ~~BV,~~B.V., the principle subsidiary of Natur International Corp, entered into a loan agreement with Dam! Holding ~~BV,~~B.V., under which Natur Holding may borrow up to US$560,915 or €500,000. The final terms of the agreement were concluded on February 18, 2019.The full drawdown of US$560,915 was made in three tranches throughout January and February ~~2019 and was used for general expenses of Natur Holding and a partial repayment of their major supplier, as provided~~2019. It is the company’s intention to fully convert this to common stock in the ~~loan agreement. The loan amount can be made in Euros, in the same numeric amounts if certain additional conditions are met by Natur Holdings related to further capital restructuring~~third quarter of ~~Natur Holdings, which the company has already undertaken.~~2019.

Repayment is due after six months from the date of receipt of the initial funds in the Natur Holding’s account. The loan may be pre-paid in full or in part at any time. Interest, at the rate of 5% per annum, is due and payable quarterly. The loan carries a default interest rate of 11% per annum. The loan has the typical default provisions of a borrowing arrangement, including breach of the borrower obligations, bankruptcy of the borrower, significant changes in the borrower’s business, and dissolution of the borrower. The full amount of the loan is covered by the grant of a security interest in Natur Holdings.

The loan amount, if unpaid at maturity, may be converted into common stock of Natur International Corp. at the conversion price of $0.05 per common stock. The lender has agreed to a term sheet for conversion of the debt into common stock at April 29, 2019. Please refer to Note 15, subsequent events.

Related party convertible note payable at ~~March 31,~~June 30, 2019 and December 31, 2018 consisted of the following:

~~The convertible loan has been converted in the subsequent period. $8,671,743~~As at June 26, 2019 $8,830,140 of the balance was ~~settled, using series~~converted Into Series Preferred C ~~preferred shares~~stock, this stock then converted to Common stock after the increase in authorized share capital of NTRU . The remainder of the balance is currently being held as loan with the company as described and ~~the remaining $3,000,000 was converted into long term debt. Please refer to Note 15, subsequent events.~~shown in note 8.

On November 13, 2018, the Company closed a ~~Subscription Agreement~~subscription agreement and debt conversion agreement with Alpha Capital Anstalt wherein the Company granted the following warrants to purchase:

~~-A total of 33,000,000 shares of common stock, at $0.0606060 per share, exercisable for four years.~~

~~-A total of 6,000,000 shares of common stock, at $0.15 per share, exercisable for four years.~~

A summary of the status of the warrants granted is presented below for the three months ended:

	March 31, 2019				December 31, 2018				June 30, 2019				December 31, 2018
	Shares		Weighted Average Exercise Price		Shares		Weighted Average Exercise Price		Shares		Weighted Average Exercise Price		Shares		Weighted Average Exercise Price
Outstanding at beginning of period		39,000,000	$	0.074		-	$	-		39,000,000	$	0.074		-	$	-
Granted		-		-		39,000,000		0.074		-		-		39,000,000		0.074
Exercised		-		-		-		-		-		-		-		-
Expired		-		-		-		-		-		-		-		-
Outstanding at end of period		39,000,000	$	0.074		39,000,000	$	0.074		39,000,000	$	0.074		39,000,000	$	0.074

On January 16, 2019, the ~~company~~Company completed compensatory arrangements with three board members of Natur International Corp. with the following terms:

Mr. Anthony Joel Bay, through La Bay Ventures Inc., will be issued a six-year option to purchase an aggregate of 7,319,321 shares of common stock of ~~NTRU.~~the Company. The option granted by ~~NTRU~~the Company provides for equal quarterly vesting of the shares commencing March 31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at the election of ~~NTRU.~~the Company. If the service agreement is terminated for a breach thereof, all vested and unvested options will terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable for the full term.

Mr. Rudolf Derk Huisman, through Pas Beheer ~~BV,~~B.V., will be issued a six-year option to purchase an aggregate of 7,319,321 shares of common stock of ~~NTRU.~~the Company. The option granted by ~~NTRU~~the Company provides for equal quarterly vesting of the shares commencing March 31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at the election of ~~NTRU.~~the Company If the service agreement is terminated for a breach thereof, all vested and unvested options will terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable for the full term.

Ms. Ellen Berkers, through Montrose Executive Management, will be issued an aggregate of 5,800,000 share of options to purchase common stock of the Company as part of her termination arrangement dated May 30, 2019. The option granted by the Company provides for the right to exercise the shares at $.030303 per share at any time from April 1, 2022 until March 31, 2025. The option provides for cashless exercise and may be registered for resale at the election of the Company.

Mr. Robert A. Paladino, through Cavalier Aire LLC., will be issued a six-year option to purchase an aggregate of 7,319,321 shares of common stock of NTRU. The option granted by ~~NTRU~~the Company provides for equal quarterly vesting of the shares commencing March 31, 2019, over three years ending December 31, 2021, with the right to exercise vested shares at $.030303 per share at any time until March 31, 2025, the sixth-year anniversary. The option provides for cashless exercise and may be registered for resale at the election of ~~NTRU.~~the Company. If the service agreement is terminated for a breach thereof, all vested and unvested options will terminate, but if the service agreement is otherwise terminated, then only then vested options will continue to be exercisable for the full term.

A summary of the status of the share options is presented below for the ~~three~~six months ended:

	March 31, 2019				December 31, 2018				June 30, 2019				December 31, 2018
	Shares		Weighted Average Fair Value		Shares		Weighted Average Fair Value		Shares		Weighted Average Fair Value		Shares		Weighted Average Fair Value
Outstanding at beginning of period		-	$	-		-	$	-		-	$	-		-	$	-
Vested		1,829,844		0.071		-		-		9,459,688		0.071		-		-
Unvested		20,128,119								18,298,275
Exercised		-		0.071		-		-		-		0.071		-		-
Expired		-		-		-		-		-		-		-		-
Outstanding at end of period		21,957,963	$	0.071		-	$	-		27,757,963	$	0.071		-	$	-

The fair value of all stock options outstanding at ~~31 March,~~30 June, 2019 is ~~$1,559,013~~$1,970,813 at a weighted average fair value of $0.071 per option.

The Company leases identified assets comprising real estate. Real estate leases consist primarily of office space. At the inception of a contract, the Company assesses whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the term, and (3) whether the Company has the right to direct the use of the asset. At inception of a lease, the Company allocates the consideration in the contract to each lease and non-lease component based on the component’s relative stand-alone price to determine the lease payments. Lease and non-lease components are accounted for separately.

Leases are classified as either finance leases or operating leases based on criteria in Accounting Standards Codification (“ASC”) 842. The Company’s operating leases are generally comprised of real estate. Operating leases are included shown separately in the unaudited consolidated balance sheet. On adoption of ASC 842 the Company recorded operating lease right-of-use assets of $580,310 and operating lease liabilities of $578,007. We do not believe the standard will materially affect our consolidated net earnings.

Right-of-use (“ROU”) assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company’s leases generally do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the implicit rate cannot be determined. ROU assets also include any lease payments made and exclude lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

Lease expense for operating leases, consisting of lease payments, is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the ROU asset on a straight-line basis over the asset’s estimated useful life and interest expense calculated using the amortized cost basis.

The Company’s leases have remaining lease terms of less than 3 years, which include options to extend the leases for up to five years, and some of which include options to terminate the leases within one year. The Company has elected not to recognize ROU assets and lease liabilities for short-term operating leases that have a term of 12 months or less. The effect of short-term leases on the Company’s ROU assets and lease liabilities was not material.

~~As of March 31, 2019, our operating leases have a weighted-average remaining lease term of 2.25 years and a weighted-average discount rate of 4%.~~

~~The future minimum obligations under operating leases in effect as of December 31, 2018 having a noncancelable term in excess of one year as determined prior to the adoption of ASC 842 are as follows:~~

At ~~March 31,~~June 30, 2019, the Company had ~~131,425,194~~310,597,593 shares issues and outstanding at a ~~nominal~~par value of $.001. ~~besides that, the~~The Company also has 2,397.130 preferred A shares issued and ~~100,000 preferred B shares.~~outstanding. Alpha ~~capital~~Capital Anstalt has two outstanding warrants issued aton November 13, 2018, each with ~~4 years term.~~4-year terms. The first warrant has an exercise price of ~~$0.0606~~$0.060606 for 36,000,000 shares and the second warrant is exercisable for 6,000,000 shares at a $0.15 exercise ~~price, the company~~price. The Company has reserved 16,240,000 shares of Common Stock for management ~~and Employee Stock Ownership Plan.~~incentive awards. At December 31, 2018, the Company had 129,049,192 shares of common stock issued and outstanding.

~~Because the company is in a net loss position, basic and diluted earnings per share are the same as the inclusion of potential dilutable shares would be anti-dilutive.~~

Effective November 30, 2018, the Company ~~has~~ closed ~~down~~ the London office and shops as part of the restructuring plan. Functionally the operations were shut down before December 31, 2018, and therefore we have qualified it as discontinued operations the sale of assets is in process. The existing support functions ~~have been~~were transferred to the headquarters in Amsterdam as part of the centralization of support staff initiative.

As of March 22, 2019, the company Naturalicious UK Limited ~~has been~~was put into liquidation and the matters are being dealt with by a qualified administration firm in the United Kingdom. A board meeting was held on March 22, 2019, ~~with all creditors~~ and it was agreed to liquidate the company. ~~At this moment in time~~Currently the rights &and obligations of the company are handled by the administration firm and the legal obligation over the liabilities are extinguished. As ~~the parent company~~we no longer ~~has~~have any rights or obligations to the indirect subsidiary, it has been removed from the consolidation and the net liability position of the company is released and recognized as a gain on disposal.

Effective August 31, 2018, ~~Natur International Corp~~the Company offices in Casper, Wyoming were closed at the ~~offices~~termination of its ~~Casper, Wyoming operations.~~health care operations.. The increase in costs coupled with a decrease in business activity, ~~lead~~led to the decision to close the Casper, Wyoming operations. In closing the office, the Company transitioned its clients to new service providers, and terminated employees as the transition happened. The month to month lease was terminated with the landlord on August 31, 2018.

In line with the objective to secure the continuity of the Company, it was decided late 2018 to extend the product line with added functional extracts (Nutrigenomics, hemp-derived extracts). For this, the Company established Natur BPS B.V. (formerly Natur CBD B.V.) as a sister company of Natur Holding B.V. at March 13, 2019, wholly owned by Natur International Corp. Based on global developments and following the ~~office~~success of companies in the USA and Canada, the Company defined new growth objectives with complementary products based on hemp-derived extracts as a new revenue model. Additional funding was ~~closed~~sought in the ~~same day. We have one part-time employee, working remotely, primarily~~market, but it became apparent that the willingness of new investors to provide the company with funding in debt or equity was dependent on the ~~collection~~restructuring of ~~accounts receivable.~~the existing debt on the balance sheet of the Company. As most of this debt is held on the balance sheet of Natur Holding B.V., it was decided to develop a restructuring plan to:

In May 2019 we reached agreements with most of the debtholders to convert their debt to equity and effective from May 1, 2019, the asset transfer between Natur Holding B.V. and its sister company Natur BPS B.V was executed and Natur Holding B.V. and its wholly owned subsidiaries were declared bankrupt by the Court in Amsterdam, the Netherlands. The total debt that was converted to shares of common stock to be issued is $ 6,754,575.

In June we reached agreement with private investors for the sale of preferred stock and warrants. At June 30, 2019, agreements were signed for a total of $2,064,756 against 65,621.283 of to be issued shares of several series of preferred stock.

NOTE 1413 – DISCONTINUED OPERATIONS AND ASSETS/LIABILITIES HELD FOR DISPOSAL - continued

The following table presents the carrying amounts of the major classes of assets and liabilities included in our discontinued operations as presented on our Unaudited Consolidated Balance Sheet as of ~~March 31,~~June 30, 2019.

	March 31, 2019		December 31, 2018		For the Six Months		December 31, 2018
Current assets
Cash and cash equivalents		-		-		-		-
Related party receivable		-		201,907		-		201,907
Accounts receivable		339		124,016		-		124,016
Inventories		-		-		-		-
Other current assets		-		51,705		-		51,705
Total current assets		339		377,628		-		377,628

Fixed Assets
Tangible fixed assets		-		27,547		-		27,547
Financial Fixed Assets		-		23,618		-		23,618
Total fixed assets		-		51,165		-		51,165

TOTAL ASSETS		339		428,794		-		428,793

Current Liabilities
Short term debt
Accounts Payable		25,692		643,616		36,894		643,616
Accrued expenses & other contingent liabilities		125,575		243,510		133,575		243,510
Total Liabilities		151,267		887,126
Total short-term debt						170,469		887,126

Effective March 31, 2019, Natur International Corp closed the offices of its Billings, Montana operations. These operations were discontinued during 2018. During 2018, the Company saw a continued decrease in the utilization of our home healthcare services in Billings, Montana. Additionally, we have seen an increase in competition, specifically for Medicare service providers in 2018. Also, there has been a shortage of Registered Nurses, Physical Therapists and management personnel, leading to higher costs due to having to source the required talent from staffing companies. This increase in costs coupled with a decrease in business activity, lead to the decision to close the Billings, Montana operations. In closing the office, the Company transitioned its clients to new service providers, and terminated employees as the transition happened. The month to month lease will be terminated with the landlord on March 31, 2019. We have one part-time employee, working remotely, primarily on the collection of accounts receivable.

~~Effective April 9,~~July 2019 the Company ~~and 6~~^th ~~Wave Efficiency Life Fund have agreed & executed a contract~~reached agreement with certain non-US private investors to ~~settle a portion~~invest in total $1,765,605 to acquire 46,947.368 of the ~~amounts owed~~Series G Preferred Stock. These preferred shares have registration rights.

On July 25, 2019 the Company entered into a Purchase and Recapitalization Agreement (“Recapitalization Agreement”) with DRBG Holdco, LLC, a Delaware limited liability company, Temple Turmeric, Inc., a Delaware corporation, Daniel Sullivan, Tim Quick, and TQ Holdings LLC, a New Hampshire limited liability company to acquire the business of Temple. Under the Recapitalization Agreement the Company acquired 15,121,984 shares of Series A Preferred Stock of Temple from DRBG for a nominal amount and acquired from TQH a promissory note in the principal amount of $100,000, plus all accrued and unpaid interest. As part of the transaction Temple issued to DRBG a warrant to acquire a percentage of the Temple equity. The Temple board of directors will have three of the five directors appointed by the Company pursuant to the Holder under the Debt Agreement, including principle, interest expenses, penalties and other charges of whatsoever nature, all in an amount equal to USD 8,846,208 (the “Converted Debt”) in exchange for and in consideration of the issuance to Holder or its designees by the Parent Company of an aggregate of 78,832,399 shares of Class C Preferred Stock (“Debt Repayment Shares”), convertible initially into the equivalent of 78,832,399 shares of Common Stock of the Parent Company (the “Conversion Shares”). The condition precedent to the agreement, the issuance of the Debt Repayment Shares was completed April 9, 2019.

~~The Holder 6~~^th Wave Efficiency Life Fund agrees that if it sells any of the shares of Common Stock it was directly or beneficially issued by the Parent Company on November 13, 2018, either as shares of Common Stock or the Common Stock underlying the Class B Preferred Stock, in exchange for its equity interest in the Company and any of the Conversion Shares (together the Common Stock, the Common Stock underlying the Class B Preferred Stock and the Conversion Shares are referred to as the “Value Calculation Shares”) at any time prior to December 31, 2022, and the gross proceeds to the Holder or its affiliates from the sale (or deemed sale as provided herein) of any or all of the Value Calculation Shares exceeds USD $15,000,000, then the balance of the Debt, equal to USD $3,000,000 as of the date hereof and any interest, expenses, penalties, and other charges of any nature due thereon under the terms of the ~~Debt Agreement (the “Debt Balance”), will be deemed~~Series A Shares. The Series A Shares represent an approximate 52% of the equity of Temple, on a fully ~~paid, discharged and extinguished and the Debt Agreement in all respects will be terminated and of no further effect.~~diluted basis.

~~Corporate restructuring~~Under the Recapitalization Agreement the Company will provide working capital to Temple in the amount of not less than $150,000 but up to $250,000. The Company will acquire additional equity ownership of Temple for this investment based on a valuation of Temple of $1,000,000. This further investment will increase the controlling position of the Company in combination with its ownership of the Series A Shares.

~~In line with~~The Temple warrant is exercisable for the ~~objective to secure the continuity~~greater of 1,493,735 shares of common stock of Temple or 2.5% of the ~~company, it was decided late 2018~~equity of Temple on a fully diluted basis. The exercise price per share is the par value of the common stock to ~~extend~~be acquired upon exercise of the ~~product line with added functional extracts (Nutrigenomics, hemp-derived extracts). For this,~~Temple warrant. The exercise period is ten years, but not later than the ~~company established~~earlier of the consummation of the initial public offering by Temple or a ~~NewCo~~sale transaction of Temple, as ~~sister~~defined in the Warrant. The Temple warrant has a cashless conversion right and has typical anti-dilution rights for dividends, reverse splits and changes in the capitalization of Temple.

On July 19, 2019, the board of directors of the Company appointed Mr. Paul Bartley as the Chief Executive Officer of the Company and appointed him to be a director of the Company, filling one of the existing vacancies on the Board of Directors. On June 30, 2019, the Company lent to Share International Holding B.V. a company of ~~Natur Holding BV~~which Mr. Bartley is a principal, the sum $250,000 under a promissory note, due January 4, 2020. The note bears interest at ~~March 13, 2019, wholly owned by~~the rate of 10%. SIH requested the loan to finance the costs relating to the conclusion of the merger such as extensive travel, third party consultancy fees and legal costs. Natur International Corp. ~~Based on global developments and following~~was willing to provide the ~~success~~loan pending the outcome of ~~companies~~the merger discussions.

The repayment obligation under the note will be cancelled if no business arrangement is concluded due to a breach by the Company of any agreement for the business arrangement that is concluded in the ~~USA and Canada,~~future, either party to the ~~company defined new growth objectives with~~note experiences a material adverse change, or the business arrangement is not approved by the shareholders or owners of the respective parties to the extent that approval is required. The note also has other standard default provisions under which the Company may declare a default.

On July 29, 2019, $639,784 of an outstanding loan facility in the principle amount of $581,058 or €500,000 plus accrued interest, at an interest rate of 10% per annum, was converted to common stock of the company. On this date the debt was converted and 11,632,445 of common stock was issued to the borrower.

complementary products based on hemp-derived extracts as a new revenue model for this NewCo. Additional funding was sought in the market, but it became apparent that the willingness of new investors to provide the company with funding in debt or equity was dependent on the restructuring of the existing debt on the Balance Sheet of the Company. As most of this debt is held on the Balance Sheet of Natur Holding BV, it was decided to develop a restructuring plan to:

The related party loan of Tridutch Holding BV and related party liabilities of STB Family Offices BV and Flare Media BV totaling $1,382,472 were transferred to NL Life Sciences BV at May 8, 2019 as part of a debt transfer agreement.

As discussed in Note 1 – Organization and nature of business, effective November 13, 2018, Future Healthcare of America entered into a reverse capitalization transaction with Natur Holding ~~BV.~~B.V. In conjunction with the transaction the Company was recapitalized, resulting in the capital structure outlined below. The main purpose of the ~~merger is~~transaction was to raise additional capital for the purposes of growth. The historical number of common shares of Nature Holding B.V. presented in our financial statements were converted to ~~post merger~~post-acquisition shares on a 1 to 112 basis. ~~As part of the recapitalization net assets of $1.9 million.~~

The following shares of common stock were issued ~~subsequent to~~in connection with the reverse ~~capitalization.~~capitalization transaction. Natur shareholders had a controlling voting percentage of 94% subsequent to the ~~reversed merger:~~transaction:

On November 13, 2018, Future Healthcare of America ~~(“Parent Company”)~~ completed ~~the~~a transactions ~~(the “Share Exchange Transaction”) contemplated by that certain~~pursuant to the Share Exchange Agreement ~~among Parent Company and the former shareholders of Natur Holdings, B.V., a Netherlands-based holding company (“Natur”).~~discussed in Note 1. In connection with the Share Exchange Transaction, the ~~former shareholders of Natur received~~Company issued the equivalent of 215,759,999 shares of the Common Stock to the former shareholders of ~~Parent Company (the “Common Stock”)~~Nature Holding B.V., which was issued in part as 115,760,000 shares of Common Stock and in part as 100,000 shares of voting, convertible Series B Preferred Stock ~~of Parent Company~~ (the “Series B Preferred Stock”) representing 100,000,000 shares of Common Stock upon conversion. The Series B Preferred Stock ~~will convert~~converted automatically ~~upon Parent Company increasing~~into the ~~number of shares of~~ Common Stock ofon June 26, 2019, when the Company increased its authorized capital in sufficient amount to permit the conversion of the Series B Preferred ~~Stock, which it plans to do promptly so as to cause the conversion of the Series B Preferred~~ Stock. Immediately after the Share Exchange Transaction, the former Natur shareholders collectively have a controlling position among the shareholders of Parent Company, and Natur has become a wholly-owned subsidiary of Parent Company. At closing the number of common shares, issued and outstanding was ~~129,049,192.~~322,230,038. Per the OTC listing the shares were officially converted on the July 2, 2019.

On September 21, 2018, Parent Company also executed a Securities Purchase Agreement (the “SPA”) by which it agreed to privately issue and sell to Alpha Capital Anstalt (the “Alpha”) ~~2,469,131~~2,469.131 shares of non-voting, convertible Series A Preferred Stock, each share convertible into approximately 3333,000 shares of Common Stock, ~~at the~~based on a per common share conversion rate of $.030303. Alpha also purchased two warrants, one pursuant to the SPA that is exercisable for 33,000,000 shares of Common Stock at $.060606 per share and another one pursuant to a debt cancellation agreement exercisable for 6,000,000 shares of Common Stock at $.15 per share. The aggregate purchase price for the Series A Preferred Stock and the ~~two warrants~~warrant for 33,333,000 shares of common stock was $2,000,000 in cash and conversion of ~~approximately $769,000~~$469,131 of ~~debt and~~outstanding debt. The other warrant was issued for conversion of outstanding interest due Alpha ~~from Parent Company~~ under a prior loan ~~agreement.~~agreement to Future Healthcare of America. Prior to the acquisition of Natur Holding, B.V., Alpha also had cancelled approximately $651,000 of debt principle and interest due from ~~Parent~~the Company. These transactions eliminated $1,420,000 of debt principle and interest of ~~Parent~~the Company and improved its balance sheet. As part of the SPA transaction, Alpha has also agreed to reimburse up to $100,000 of the liabilities of Parent Company existing at the closing ~~date.~~date, which has not yet been paid.

On March 19, 2019, the holder of the Series A Preferred Stock converted 72 of such shares with a stated value of $72,000 for 2,376,002 shares of common stock. The applicable conversion price per common share was $0.030303. The ~~company~~Company did not receive any payment on this conversion, having received the consideration for the Series A Preferred Shares on November 12, 2018. There are remaining an aggregate of 2,397.131 shares of Series A Preferred Stock issued and outstanding. The shares of common stock issued on conversion are registered for resale by the holder.

On April 4, 2019, the Company filed an Articles of Amendment in the State of Wyoming to create a new class of Series C Preferred Stock, which was returned as of April 9, 2019. The Series C Preferred Stock was converted into 78,832,399 shares of Common Stock on June 26, 2019. Per the OTC listing the shares were officially converted on the July 2, 2019.

In June 2019, the Company has entered into a series of agreements under which it will be required to issue the following different series of preferred stock, subject to certain conditions precedent.

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Statements made in this Form 10-Q which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company, including, without limitation, ~~(i)~~ our ability to gain a larger share of the ~~home healthcare industry,~~markets in which we offer our ~~ability to continue to develop services acceptable to our industry,~~beverage and other products, our ability to retain our business relationships, ~~and~~ our ability to raise capital and ~~the growth of the home healthcare industry,~~our ability to consolidate our business operations, acquisitions and ~~(ii) statements~~grow our product offerings to meet consumer demands, Statements preceded by, followed by or that include the words “may”, “would”, “could”, “should”, “expects”, “projects”, “anticipates”, “believes”, “estimates”, “plans”, “intends”, “targets”, “tend” or similar ~~expressions.~~expressions indicate forward-looking statements.

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Company’s control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following, in addition to those contained in the Company’s reports on file with the Securities and Exchange Commission: general economic or industry conditions ~~nationally and/or~~ in the national and local communities in which the Company conducts business and sells its products, changes in the ~~interest rate environment,~~ legislation or regulatory requirements ~~conditions of~~that affect our products and their composition and the ~~securities markets, changes in the home healthcare industry,~~locations through and to which they can be transported and sold, the development of ~~services~~products that may be superior to ~~the services~~those offered by the Company, competition in our product segments, changes in the quality or composition of the Company’s ~~services,~~products, our ability to develop new ~~services,~~products, our ability to raise capital, conditions in the securities markets that may affect the price and trading of our securities held by investors, changes in accounting principles, ~~policies or guidelines, financial or political instability, acts of war or terrorism,~~and other ~~economic, competitive,~~ governmental, regulatory and technical factors affecting the Company’s ~~operations, services and prices.~~operations.

Accordingly, results actually achieved may differ materially from expected results in these statements. Forward-looking statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

~~Natur~~The Company is committing to meet the demands of the burgeoning market for healthy food & beverage products beyond our award-winning fruit and vegetable juices and snacks. The Company is preparing for launch of a wider range of foods and beverages that are effectively functional. With consumers in increasing numbers eating more frequently, eating socially and being focused on the wellness derived from their choices, ~~Natur is~~we are offering choices that can boost their immune system, support a sense of equilibrium in a stressful life, help to resist foods that are not healthy, and more.

~~Natur~~The Company brings the forces of nature, existing naturally and organically, as functional supplements in our branded foods and beverages. The first of nature’s superfoods to join our line is hemp. We are preparing for ~~launch in~~ the ~~Spring~~launch of our line of juices and snacks infused with hemp-derived extracts that are intended to offer improvement in quality of life. The human body’s endo-cannabinoid system is starved for sources of external cannabinoids. When fed, this system fires up the forces of immunity, pain management, heart health, a sense of equilibrium and much more. The Forces of Nature, from the industrial hemp plant, in their purest form, provide the best source for these important cannabinoids. These hemp-derived extracts are the non-psychoactive cannabinoid in the hemp plant that, in increasing numbers, is gain consumer fans for its potential role in treating many common health issues, including pain, inflammation, anxiety, depression, acne and heart disease.

Anticipating growing demand, Natur is developing collaborations in hemp cultivation, extraction and innovation – with growers, greenhouses, research and development scientists driving new products in the fields of hemp-derived medication, edibles and beverages, human and animal topicals and wellness products.

The 2019 Plan provides for grants of both incentive stock options, or “ISOs”, which are subject to special income tax treatment, and non-statutory options, or “NSOs.” Eligibility for ISOs is limited to employees of the Company and its subsidiaries. The exercise price of an ISO cannot be less than the fair market value of the common stock at the time of grant. In addition, the expiration date of an ISO cannot be more than ten years after the date of the original grant. In the case of NSOs, the exercise price and the expiration date are determined in the discretion of the administrator. The administrator also determines all other terms and conditions related to the exercise of an option, including the consideration to be paid, if any, for the grant of the option, the time at which options may be exercised and conditions related to the exercise of options.

The 2019 Plan also provides for awards of shares of restricted common stock. Awards of restricted stock may be made in exchange for past services or other lawful consideration. Generally, awards of restricted stock are subject to the requirement that the shares be forfeited or resold to the Company unless specified conditions are met. Subject to these restrictions, conditions and forfeiture provisions, any recipient of an award of restricted stock will have all the rights of a stockholder of the Company, including the right to vote the shares and to receive dividends. The 2019 Plan also provides for deferred grants (“deferred stock”) entitling the recipient to receive shares of common stock in the future on such conditions as the administrator may specify.

On April 4, 2019, the Company filed an Articles of Amendment in the State of Wyoming to create a new class of Series C Preferred Stock, which was returned as of April 9, 2019. The Series C Preferred Stock has a liquidation preference of $112.20 per share. Each share of Series C Preferred Stock may be converted into 1,000 shares of Common Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization) without the payment of any additional consideration by the holders thereof. The Series C Preferred Stock automatically converts into 78,832,399 shares of Common Stock upon the six-month anniversary of the Conversion Agreement if there has been an increase in the common stock capitalization of the Company. The holders of Series C Preferred Stock are entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C Preferred Stock are convertible on all matters presented to the shareholders.

During the quarter ended ~~March 31,~~June 30, 2019, the Company ~~completed seating~~focused its newly installed board of directors and appointed a new Chief Executive Officer, adopting a fresh direction for the Company. Practical decisions were made with regard to the existing business and customer base basedefforts on the ~~contribution~~restructuring of its business in the Netherlands and the restructuring of the debt, at the same time the first steps were set to activate the new ~~vision~~business plan. Discussions with potential merger partners and ~~mission and to profitability.~~private investors took considerable time during this quarter

For the quarter, while sales revenues were considerably lower year over year, operating losses were also lower. Contributing to negative margins was the reduction of inventories through liquidation.

Three Months Ended ~~31 March,~~30 June, 2019 versus Three Months Ended ~~31 March~~30 June 2018

During the three months ended ~~March 31,~~June 30, 2019, Natur recorded revenues of ~~$64,419, an 88%~~$8,134, a 98% decrease over revenues of ~~$527,717~~$414,716 for the same period in 2018. The decrease in 2019 is attributed to the decision the ~~company~~Company made to discontinue selling to less profitable customers while developing its new culturally relevant product lines. It should be noted that in Q1Q2 2018, ~~the introduction of~~revenues were generated by two large ~~customers generated initial opening orders, filling the supply chain.~~customers. Both of these customers proved to be less beneficial to the business than planned and by the beginning of Q1 2019 sales to these customers were discontinued.

With the lower revenues in the quarter, cost of goods sold included unleveraged warehousing, inventory reduction and product discard costs and totaled ~~$94,777,~~$4,919, a ~~65%~~99% decrease as compared to ~~$273,752~~$283,400 in the comparable period of 2018. Natur posted a gross profit of $3,215 during the second quarter 2019, versus a gross loss of $131,316 for the second quarter of 2018.

During the six months ended June 30, 2019, Natur recorded revenues of $72,553, a 92% decrease over revenues of $942,433 for the same period in 2018. The decrease in 2019 is attributed to the decision the company made to discontinue selling to less profitable customers while developing its new culturally relevant product lines. It should be noted that in first half of 2018, the introduction of two large customers generated initial opening orders, filling the supply chain. Both of these customers proved to be less beneficial to the business than planned and by the beginning of Q1 2019 sales to these customers were discontinued.

With the lower revenues in the six-month period, cost of goods sold included unleveraged warehousing, inventory reduction and product discard costs and totaled $99,696, an 82% decrease as compared to $557,152 in the comparable period of 2018. Natur posted a gross loss of ~~$30,358~~$27,143 during the first ~~quarter~~half of 2019, versus a gross profit of ~~$253,965~~$385,281 for the first ~~quarter~~half of 2018.

Natur ~~made~~continued to make year over year improvements in some controllable costs while recording total operating expenses of ~~$1,939,328~~$3,294,333 during the first ~~quarter~~half of 2019, a ~~17%~~14% increase as compared to operating expenses of ~~$1,611,564~~$2,895,729 in the same period of 2018. Wages & Salaries showed a strong improvement, totaling ~~$264,729~~$373,064 in the first ~~quarter~~half of 2019 versus ~~$443,381~~$792,679 in the first ~~quarter~~half of 2018, a decrease of ~~40%~~53% driven by significantly streamlined head-count compared to ~~Q1 of~~ 2018. AAn additional strong contributing factor is the discontinuation of retail store activities in both the UK and the Netherlands. Selling, General & Administrative costs increased to ~~$1,402,410~~$2,645,471 from ~~$1,114,867~~$2,019,466 when comparing the first ~~quarter~~half of 2019 versus 2018, or ~~26%~~31%. This was driven mainly by an increase in the overall costs incurred by the business due to the administration costs of maintaining a public listing such as legal, board &and accountancy fees. The ~~company~~Company also introduced a stock option scheme in 2019 with no similar such costs in the first ~~quarter~~half of ~~2018.~~2018 with costs totaling $1,088,206 for 2019 . Amortization ~~& Depreciation~~depreciation and impairment costs increased to ~~$272,189~~$275,798 from ~~$53,316~~$83,584 when comparing the first ~~quarter~~half of 2019 versus 2018, or ~~411%~~230%. This was driven mainly by the ~~company~~Company taking a prudent measure to write down all assets in the retail stores ~~(roughly $200k)~~(approximately $200,000) to Nil. As the ~~company cannot~~Company could not comfortably assume we ~~will~~would receive any proceeds for these assets it will therefore only take gains on disposal in future periods should they be realized. These assets are now with the Curator pursuant to the Petition who is dealing with the liquidation of Natur Holding B.V.

Natur’s net loss available to common shareholders was ~~$1,747,531~~$1,551,207 for the first ~~quarter~~half of 2019. This represents a ~~20%~~58% decrease from our net loss of ~~$2,179,184~~$3,669,410 in the first ~~quarter~~half of 2018. The decrease in the loss was partially offset due to the liquidation of the UK business and a number of the subsidiaries in the Netherlands which allowed a gain on disposal of ~~$300,798~~$1,891,985 to be realized.

Three Months Ended ~~31 March,~~30 June, 2019 versus Three Months Ended 31 ~~December 2018~~March 2019

During the three months ended ~~March 31,~~June 30, 2019, Natur recorded revenues of ~~$64,419, a 63%~~$8,134, an 87% decrease over revenues of ~~$173,378~~$64,419 for the preceding period. The decrease ~~for 2019~~against the quarters was driven by the fact that ~~in Q4 2018 we received wind-down revenues from two former customers of $102,000. We have received no such orders in Q1 2019 due~~the companies focus for the quarter was on restructuring and seeking funding that would allow the business to continue as a going concern. The focus moving forward into the ~~strategic focus change~~second half of the ~~business.~~year is to engage revenues as part of the Company’s new strategic focus.

For the quarter ended ~~March 31,~~June 30, 2019, cost of goods sold totaled ~~$94,777,~~$4,919, a ~~48%~~91% decrease as compared to ~~$183,777~~$94,777 in the preceding period of ~~2018.~~2019. This reflects the costs associated with the overall reduction of revenue and due to the reduction in sales the ~~company has~~Company had experienced higher marginal costs for our ~~warehousing.~~warehousing in the first quarter which have now been largely reduced. We ~~have~~ also experienced higher disposal costs due to the perishable nature of our ~~products.~~products in the first quarter of 2019. Natur posted a gross ~~loss~~profit of ~~$30,358~~$3,215 during the ~~first~~second quarter 2019, versus a gross loss of ~~$10,039~~$30,358 for the preceding quarter of ~~2018.~~2019.

Natur recorded total operating expenses of ~~$1,939,328~~$1,355,005 during the ~~first~~second quarter of 2019, a ~~17% increase~~30% decrease as compared to operating expenses of ~~$1,598,974~~$1,939,328 in the preceding period. Wages & Salaries totaled ~~$264,729~~$108,335 in the ~~first~~second quarter of 2019 versus ~~$267,511~~$264,729 in the preceding quarter a decrease of ~~1%.~~59% driven by significantly streamlined head-count compared to the first quarter. An additional strong contributing factor is the discontinuation of retail store activities in both the UK and the Netherlands. Selling, General & Administrative costs ~~increased~~decreased to ~~$1,402,410~~$1,243,061 from ~~$1,279,731~~$1,402,410 when comparing the preceding quarter, or ~~21%~~11%. This was driven mainly by ~~an increase~~a decrease in the overall costs incurred by the business due to the administration costs of maintaining a public listing ~~such~~ as ~~legal & accountancy fees.~~processes have been strengthened and we have undertaken less advisory work in the quarter. The ~~company~~was slightly offset by the fact that the Company also introduced a stock option scheme in 2019 with ~~no similar such~~higher costs in the ~~last~~second quarter due to the termination agreement with Ms. Ellen Berkers. Amortization depreciation & impairment costs decreased to $3,609 from $272,189 when comparing the second quarter of ~~2018. Amortization & Depreciation costs increased to $272,189 from $51,732 when comparing~~2019 versus the first quarter of 2019, ~~versus the fourth quarter of 2018,~~ or ~~426%~~99%. This was driven mainly by the ~~company~~Company taking a prudent measure to write down all assets in the retail stores (roughly $200k) to ~~Nil.~~Nil in the first quarter. As the ~~company cannot~~Company could not comfortably assume we ~~will~~would receive any proceeds for these assets it will therefore only take gains on disposal in future periods should they be realized. These assets are now with the Curator pursuant to the Petition who is dealing with the liquidation of the company.

Natur’s net ~~loss~~profit available to common shareholders was ~~$1,747,531~~$196,324 for the ~~first~~second quarter of 2019. This represents a ~~21% increase~~strong improvement from our net loss of ~~$2,144,114~~$1,747,531 in the ~~last~~first quarter of ~~2018.~~2019. The ~~increase~~gain was partially by the corporate restructuring and the decision to close the UK business and a number of the company’s subsidiaries in the ~~loss was partially offset due to the liquidation of the UK business~~Netherlands which allowed a gain on disposal of ~~$300,798~~$1,891,985 to be realized.

Debt restructuring - Effective ~~April 9,~~June 30, 2019 the Company and ~~6th Wave Efficiency Life Fund~~most of its debtholders have agreed &and executed ~~a contract~~contracts to settle ~~a portion of~~ the amounts owed by the Company to the ~~Holder~~holders under individual the ~~Debt Agreement,~~debt agreements, including principle, interest expenses, penalties and other charges of whatsoever nature, all in an amount equal to ~~USD 8,846,208 (the “Converted Debt”)~~$6,754,575 in exchange for and in consideration of the issuance to ~~Holder or its designees~~ by the ~~Parent~~ Company of an aggregate of ~~78,832,399 shares of Class C Preferred Stock (“Debt Repayment Shares”), convertible initially into the equivalent of 78,832,399~~161,149,309 shares of Common ~~Stock of the Parent Company (the “Conversion Shares”). The condition precedent to the agreement, the issuance of the Debt Repayment Shares was completed April 9, 2019.~~Stock.

~~The company has made further agreements, subject to board approval, confirming to agree to the principle of debt conversion to shares of the company to the following debtholders:~~

Corporate restructuring - In line with the objective to secure the continuity of the ~~company,~~Company, it was decided in late 2018 to extend the product line with ~~added~~the addition of functional extracts (Nutrigenomics, ~~hemp-derived)~~hemp-derived extracts). For this, the ~~company~~Company established ~~a NewCo as a sister company of~~ Natur ~~Holding BV~~CBC B.V. at March 13, 2019, wholly owned by Natur International Corp. Based on global developments and following the success of companies in the USA and Canada, the ~~company~~Company defined new growth objectives with complementary products based on hemp-derived extracts as a new revenue ~~model for this NewCo.~~model. Additional funding was sought in the market, but it became apparent that the willingness of new investors to provide the company with funding in debt or equity was dependent on the restructuring of the existing debt ~~on the Balance Sheet~~ of the Company. As most of this debt ~~is held on~~exists at the ~~Balance Sheet~~level of Natur Holding ~~BV,~~B.V., it was decided to develop a restructuring plan to: establish an asset transfer from Natur Holding B.V. to Natur CBD B.V., optimizing the proceeds for these assets and subsequently liquidate Natur Holding B.V. and continue the business in Natur CBD B.V. with an extended portfolio of functional products, including food and beverages infused with hemp-derived extracts and deliver the objectives as set by the Board.

In May 2019 we reached agreements with most of the debtholders to convert their debt to equity and effectively May 1, 2019 the asset transfer between Natur Holding B.V. and its sister company Natur Functionals B.V. was executed and Natur Holding B.V. and its wholly owned subsidiaries were declared bankrupt by the Court in Amsterdam, the Netherlands. The total Debt that was converted to Shares to be issued is $6,754,575.

In June we reached agreement with private investors for the sale of Preferred Stock and Warrants. At June 30, 2019 agreements were signed for a total of $2,064,756 against 65,621.283 of to be issued Preferred Shares.

ASC 842: In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. This update requires the recognition of lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous guidance. The accounting for finance leases (capital leases) was substantially unchanged. The original guidance required application on a modified retrospective basis with adjustments to the earliest comparative period presented. In August 2018, the FASB issued ASU No. 2018-11, “Targeted Improvements to ASC 842,” which included an option to not restate comparative periods in transition and elect to use the effective date of ASU No. 2016-02 as the date of initial application, which the Company elected. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, and continues to be reported under previous guidance that did not require the recognition of operating lease liabilities and corresponding lease assets on the consolidated balance sheet. As a result of the adoption of ASU No. 2016-02 on January 1, 2019, the Company recorded operating lease right-of-use assets of $580,310 and operating lease liabilities of $578,007. The adoption of ASU No. 2016-02 had an immaterial impact on the Company’s condensed consolidated statement of income and consolidated statement of cash flows for the ~~three-month~~six-month period ended ~~March 31,~~June 30, 2019. In addition, the Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company to carry forward the historical lease classification, not reassess prior conclusions related to expired or existing contracts that are or that contain leases, and not reassess the accounting for initial direct costs.

Our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)), which we refer to as disclosure controls, are controls and procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any control system. A control system, no matter how well conceived and operated, can provide only reasonable assurance that its objectives are met. No evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

As of ~~March 31,~~June 30, 2019, an evaluation was carried out under the supervision and with the participation of our management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls. Based upon that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that, as of such date, the design and operation of these disclosure controls were ~~effective~~ineffective to accomplish their objectives at the reasonable assurance level.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), occurred during the fiscal quarter ended ~~March 31,~~June, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included in Part I, Item 1 of this Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.” Our actual results may differ materially from those described below. You should read the “Risk Factors” section of this Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Certain figures, such as interest rates and other percentages included in this section have been rounded for ease of presentation. Percentage figures included in this section have not in all cases been calculated on the basis of such rounded figures but on the basis of such amounts prior to rounding. For this reason, percentage amounts in this section may vary slightly from those obtained by performing the same calculations using the figures in our consolidated financial statements or in the associated text. Certain other amounts that appear in this section may similarly not sum due to rounding.

On June 17, 2016 and June 30, 2016 two complaints were filed, one with the Federal Equal Employment Opportunity Commission (“EEOC”) and one with the Wyoming State Department of Labor against the Company, alleging discrimination on the basis of sex and disability. The complaints did not seek any specific monetary relief. The complaints were mediated by the Wyoming State Department of Labor, and the U.S. Equal Employment Opportunity Commission. The Wyoming State Department of Labor issued a notice of dismissal for one of the complaints. After reviewing the facts and circumstances, the Company believes the claims made are weak, at best, and the Company has retained counsel and intends to continue a vigorous defense. On March 6, 2018, a complaint was filed with the Wyoming Court of Natrona County, alleging violation of the Wyoming Fair Employment Practices Act of 1965 for discrimination based upon sex, disability and retaliation. The complaint does not seek any specific monetary relief. At this time, management cannot reasonably estimate the cost to defend or the outcome of the complaints.

On June 1, 2018, The U.S. EEOC ~~made a determination~~decided that Interim Healthcare of Wyoming violated the Wage discrimination laws (Title VII of the Civil Rights Act of 1964) by paying a male employee more than female employees. The EEOC initially claimed that back wages for these individuals plus liquidated damages total $43,593. On September 19, 2018, the Company attended a Conciliation meeting, at which the EEOC presented a revised settlement of $133,575 for back wages plus liquidated damages. The Company and the EEOC did not agree to a resolution. On September 28, 2018, the EEOC filed in the U.S. District Court for the District of Wyoming a complaint claiming Interim Healthcare of Wyoming violated the Wage discrimination laws (Title VII of the Civil Rights Act of 1964) by paying a male employee more than female employees. It is too early to provide an educated opinion on the chances of a favorable outcome in this matter. There was a wage disparity present at Interim such that a male RN nurse employee was earning $1-$2 more per hour than all other RN nurse employees who were female. Interim employed approximately 6 female RN nurses, and this wage disparity existed for approximately 1 year of operation. We have asserted that this wage disparity was the result of market factors and not illegal gender discrimination, however whether we will be able to marshal sufficient evidence to overcome the presumption that arises from the admitted wage disparity. The Company recorded an accrual totaling $133,575 related to this ~~matter.~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WYOMING		45-5547692
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging Growth company ☒☐

~~Unaudited~~ Consolidated Balance Sheets	2

Unaudited Consolidated Statements of Operations	3

Unaudited Consolidated Statements of Cash Flows	5

Notes to Unaudited Consolidated Financial Statements	6

	March 31, 2019 (unaudited)			March 31, 2018

REVENUE		64,419			527,717

COST OF GOODS SOLD - RELATED PARTY		30,881			200,354
COST OF GOODS SOLD		63,896			73,398
		94,777			273,752

GROSS MARGIN		(30,358	)		253,965

OPERATING EXPENSES
Wages & Salaries		264,729			443,381
Selling, General & Administrative		1,402,410			1,114,867
Amortization & depreciation		272,189			53,316

Total operating expenses		1,939,328			1,611,564

LOSS FROM OPERATIONS		(1,969,686	)		(1,357,599	)

Interest expense		39,233			28,848

LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES		(2,008,919	)		(1,386,447	)

Income taxes		-			-

INCOME FROM CONTINUING OPERATIONS		(2,008,919	)		(1,386,447	)

Discontinued operations (note 14)
Gain on disposal of subsidiary		300,798			-
Loss from operations of discontinued Component		(39,410	)		(792,737	)

NET LOSS ATTRIBUTE TO SHAREHOLDERS		(1,747,531	)		(2,179,184	)

Earnings Per Share		(0.01	)		(0.02	)
Diluted Earnings Per Share		(0.01	)		(0.02	)

COMPREHENSIVE INCOME

Net Loss		(1,747,531	)		(2,179,184	)
Other comprehensive income		353,913			157,681

COMPREHENSIVE LOSS		(1,393,618	)		(2,021,503	)

	For the Three Months						For the Six Months
	June 30, 2019			June 30, 2018			June 30, 2019			June 30, 2018

REVENUE		8,134			414,716			72,553			942,433

COST OF GOODS SOLD - RELATED PARTY		2,679			224,682			33,560			425,036
COST OF GOODS SOLD		2,240			58,718			66,136			132,116
		4,919			283,400			99,696			557,152

GROSS MARGIN		3,215			131,316			(27,143	)		385,281

OPERATING EXPENSES
Wages & Salaries		108,335			349,298			373,064			792,679
Selling, General & Administrative		1,243,061			904,599			2,645,471			2,019,466
Amortization , depreciation and impairment		3,609			30,268			275,798			83,584

Total operating expenses		1,355,005			1,284,165			3,294,333			2,895,729

LOSS FROM OPERATIONS		(1,351,790	)		(1,152,849	)		(3,321,476	)		(2,510,448	)

Interest expense		862			34,413			40,095			63,261

LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES		(1,352,652	)		(1,187,262	)		(3,361,571	)		(2,573,709	)

Income taxes		-			-			-			-

INCOME FROM CONTINUING OPERATIONS		(1,352,652	)		(1,187,262	)		(3,361,571	)		(2,573,709	)

Discontinued operations (NOTE 13)
Gain (loss) on disposal of subsidiary		1,591,187			-			1,891,985			-
Loss from operations of discontinued Component		(42,211	)		(302,964	)		(81,621	)		(1,095,701	)

NET PROFIT (LOSS) AVAILABLE/ATTRIBUTE TO MEMBERS		196,324			(1,490,226	)		(1,551,207	)		(3,669,410	)

Basic earnings/(loss) per share		0.00			(0.01	)		(0.00	)		(0.03	)
Diluted earnings/(loss) per share		0.00			(0.01	)		(0.00	)		(0.03	)

COMPREHENSIVE INCOME

Net Profit (Loss)		196,324			(1,490,226	)		(1,551,207	)		(3,669,410	)
Other comprehensive income		50,677			-			404,590			-

COMPREHENSIVE PROFIT (LOSS)		247,001			(1,490,226	)		(1,146,617	)		(3,669,410	)

	Common stock				Preferred A					Preferred B				Other
	Number of Shares		Amount (.001 par)		Issued shares			Amount (.001 par)		Issued shares		Amount (.001 par)		Paid in Capital			Retained deficit			Accumulated OCI			Total
Balance at December 31, 2017		115,759,999		115,760		-			-		-		-		3,316,560			(15,250,748	)		(1,114,812	)		(12,933,240	)

Net Loss																		(7,048,822	)					(7,048,822	)
Recapitalization		13,289,193		13,289		2,469.131			2		100,000		100		1,857,709									1,871,100
Other comprehensive loss																					777,687			777,687
Balance at December 31, 2018		129,049,192		129,049		2,469.131			2		100,000		100		5,174,269			(22,299,570	)		(337,125	)		(17,333,275	)

Net Loss																		(1,745,531	)					(1,745,531	)
Share-based compensation															403,162									403,162
Conversion of Preferred A to Common stock		2,376,002		2,376		(72	)		-						(2,376	)								-
Other comprehensive income																					353,913			353,913
Balance at March 31, 2019		131,425,194		131,425		2,397			2		100,000		100		5,575,055			(24,047,101	)		16,788			(18,323,731	)

	Common Stock				Preferred stock A					Preferred stock B						Preferred stock C
	Amount ($.001 par)		Number of Shares		Amount ($.001 par)		Number of Shares			Amount ($.001 par)			Number of Shares			Amount ($.001 par)			Number of Shares			Other Paid in Capital			Retained deficit			Accumulated OCI			Total
Balance at December 31, 2018		129,049		129,049,192		2		2,469.131			100			100,000			-			-			5,174,269			(22,299,570	)		(337,125	)		(17,333,275	)

Net Loss																										(1,747,531	)					(1,747,531	)
Share-based compensation																							403,162									403,162
Conversion of Preferred A to Common Stock		2,376		2,376,002		(-)		(72	)														(2,376	)								(-)
Accumulated other comprehensive gain/(loss)																													353,913			353,913
Balance at March 31, 2019		131,425		131,425,194		2		2,397.131			100			100,000			-			-			5,575,055			(24,047,101	)		16,788			(18,323,731	)
																																-
Net Profit																										196,324						196,324
Share-based compensation																							685,044									685,044
Debt Converted to Common Stock		340		340,000																			13,218									13,558
Conversion of Preferred B to Common Stock		100,000		100,000,000							(100	)		(100,000	)								(99,900	)								-
Issuance of Preferred C Stock																	79			78,832			8,830,061									8,830,140
Conversion of Preferred C to Common Stock		78,832		78,832,399													(79	)		(78,832	)		(78,753	)								-
Accumulated other comprehensive gain/(loss)																													50,677			50,677
Balance at June 30, 2019		310,597		310,597,593		2		2,397			-			-			-			-			14,924,725			(23,850,777	)		67,465			(8,547,988	)

	March 31, 2019 (unaudited)			March 31, 2018

CASHFLOW FROM OPERATING ACTIVITIES
Net Loss		(1,747,531	)		(2,179,184	)
Adjustments to reconcile net loss to net cash used in operating activities
Lease expense		65,496			-
Amortization & depreciation		267,819			53,316
Stock based compensation		403,162			-
Changes in:
- Accounts receivable		34,125			212,016
- Related party receivable		37			51,400
- Inventories		75,676			383,483
- Other current assets		21,043			(40,805	)
- Accounts payable		214,307			307,533
- Lease liabilities		(67,045	)		-
- Accrued expenses		152,367			(477,104	)
- Accrued expenses - related parties		187,049			(401,747	)
Net cash used in operating activities		(393,495	)		(2,091,092	)
Net cash used in operating activities - Discontinued operations		(358,570	)		(237,599	)

CASHFLOW FROM INVESTING ACTIVITIES
Cash paid for purchase of property and equipment		-			-
Cash received for sale of property and equipment		-			-
Net cash from in investing activities		-			-
Net cash from in investing activities - Discontinued Operations		51,165			-

CASHFLOW FROM FINANCING ACTIVITIES

Related party loan additions		-			12,330
Convertible loan note additions		560,915			-
Related party convertible loan note additions		-			1,233,046
Net cash provided from financing activities		560,915			1,245,376
Net cash from financing activities - Discontinued Operations		-			41,118

Effect of foreign exchange rate changes on cash and cash equivalents		30,221			157,681

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(109,764	)		(884,516	)

CASH AND CASH EQUIVALENTS beginning of period		128,364			1,082,734
CASH AND CASH EQUIVALENTS end of period		18,600			198,218

Category		Estimated Useful lives
Building and improvements		5 years
Machines and installations		5 years
Furniture and fixtures		7 years
Hardware and software		3 years

	~~2019~~
~~Expected dividend yield~~		0	%
~~Expected option term (years)~~		6
~~Expected volatility~~		~~382~~	%
~~Risk-free interest rate~~		3	%

	2019			2018
Expected dividend yield		0	%		-
Expected option term (years)		6			-
Expected volatility		382	%		-
Risk-free interest rate		3	%		-

	~~March 31,~~ ~~2019~~
~~Netherlands~~		~~64,419~~
~~France~~		-
~~Iceland~~		-
~~Total~~		~~64,419~~

	June 30, 2019		June 30, 2018
Netherlands		72,553		942,433
France		-		-
Iceland		-		-
Total		72,553		942,433

	March 31, 2019		December 31, 2018
Balance Sheets		0.8914		0.8734
Statements of operations and comprehensive income (loss)		0.8805		0.8464
Equity		0.9037		0.9037

	March 31, 2019		December 31, 2018

Micknifisent B.V.		1,796		1,833
		1,796		1,833

	March 31, 2019
2019	$	196,034
2020		270,649
2021		178,323

Total lease payments		645,006
Less imputed interest		66,999

Present value of lease liabilities	$	578,007

2019			436,657
2020			392,004
2021			146,759
2022			-
2023			-
Thereafter			-
Total			975,430

	June 30,			December 31,
	2019			2018
Building and improvements		-			491,847
Machines and installations		-			65,886
Furniture and fixtures		60,117			200,508
Hardware and software		-			80,163
		60,117			838,404

Less: Accumulated Depreciation & Amortization		(1,432	)		(314,894	)
		58,685			523,510

	March 31, 2019		December 31, 2018

Value Added Tax receivable		62,851		67,388
Prepaid expenses		15,550		32,054
Other Receivables		91		93
		78,492		99,535

	March 31, 2019		December 31, 2018

Taxes payable		534,254		352,423
Invoices to be received		25,572		3,972
Holiday Allowance Payable		33,584		24,642
Other accrued expenses & other contingent liabilities		29,908		202,124
		623,318		583,161

	March 31, 2019		December 31, 2018

NL Life Sciences B.V.		829,942		563,118
STB Family Offices SARL		196,193		200,234
STB Family Offices B.V.		653,190		661,432
Stichting Thank You Nature		-		16,913
Flare Media B.V.		24,944		25,458
AMC		238,945		325,382
Management & Board Fees		251,910		142,154
Yoomoo Limited		-		98,014
Dynamic Health B.V.		22,316		-
		2,217,440		2,032,705

		March 31, 2019				December 31, 2018
Convertible loan Efficiency Life Fund			11,436,228				11,671,743

	March 31, 2019		Balance Sheet Classification
Lease Assets	$	580,310	Right-of-use Asset

Current lease liabilities		263,013	Operating lease liabilities
Non-current lease liabilities		314,994	Operating lease liabilities
Total Lease Liabilities	$	578,007

	~~March 31,~~ ~~2019~~

~~REVENUE~~		-

~~COST OF GOODS SOLD~~		-

~~GROSS MARGIN~~		-

~~OPERATING EXPENSES~~
~~Wages & Salaries~~		-
~~Selling, General & Administrative~~		~~39,410~~
~~Amortization & depreciation~~		-

~~Total operating expenses~~		~~39,410~~

~~LOSS FROM OPERATIONS~~		~~(39,410~~	)

~~Interest expense~~		-

~~LOSS FROM DISCONTINUED OPERATIONS~~		~~(39,410~~	)

Name of debtholder	Currency	Amount in Euros		USD/EURO		Amount of debt in $		price per share in $		number of shares		Type of share
6th Wave Efficiency Life Fund	USD						3,450,000		0.05		69,000,000		preferred
Dam! Holding BV	EUR		505,487		1.12		566,145		0.05		11,264,700		common
Ghassan Akeel	USD						571,236		0.055		11,632,445		common
NL Life Sciences BV	EUR		2,020,000		1.12		2,262,400		0.0303031		74,659,028		preferred
STB Family Office SARL	EUR		202,877		1.12		227,222		0.0303031		7,498,309		preferred
			2,728,364				7,077,004				174,054,490

Exhibit No.		Description

31.1		302 Certification of ~~Robert A. Paladino~~Paul Bartley

31.2		302 Certification of ~~Ellen Berkers~~Ruud Huisman

32		906 Certification.

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation
101.DEF		XBRL Taxonomy Extension Definition
101.LAB		XBRL Taxonomy Extension Labels
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

	NATUR INTERNATIONAL CORP.

Date:~~15/5/~~ 8/14/19	By:	/s/ ~~Robert A. Paladino~~Paul Bartley
		~~Robert A. Paladino~~Paul Bartley
		Chief Executive Officer

Date:~~15/5/~~ 8/14/19		/s/ ~~Ellen Berkers~~Rudolf D. Huisman
		~~Ellen Berkers~~Ruud Huisman
		Chief Financial Officer